'Cure4Cancer' Hub Raising Awareness for International Clinical Trials Now Available in Chinese
NEW YORK, May 4, 2023 — Asia Society, in collaboration with Memorial Sloan Kettering Cancer Center (MSK), Bloomberg New Economy International Cancer Coalition, the Chinese Thoracic Oncology Group (CTONG), and others have jointly launched Cure4Cancer (C4C), a new online informational hub to raise public awareness about international clinical trials and their unique capacity to save lives. The new site cure4cancerglobal.org is now available in Chinese and is the first portal of its kind aiming to bring together information on international policy harmonization on clinical trials.
纽约，2023年4月26日—亚洲协会（Asia Society）与纪念斯隆-凯特琳癌症中心（MSK斯隆）、彭博创新经济国际抗癌联盟、中国胸部肿瘤研究协作组(CTONG)等机构合作，共同推出了Cure4Cancer（聚爱愈癌，简称：C4C）国际合作项目。该项目旨在通过建立新的网络信息枢纽，提高公众意识，帮助国际社会各界更深入地了解国际临床试验及其在抗癌领域拯救生命的巨大能力。网站现推出中文版本，旨在搭建首个汇集国际临床试验的政策协同相关信息的门户网站。
Together, China and the U.S. account for almost 40% of the world’s 10 million annual cancer deaths. Thus, it is paramount that Chinese data, cases, patients, and other stakeholders are connected to the global Cure4Cancer movement through the Chinese website.
中美两国每年的癌症死亡总人数占到了全世界每年1000万死亡人数的约40%。这使得中文数据、重点案例、患者以及其它相关人士和信息通过C4C中文网实现与抗癌全球社群的广泛连接显得意义非凡.
The multilingual launch, starting with Chinese, is the first step in Cure4Cancer's strategy as a global collaboration dedicated to connecting a wide range of stakeholders across languages and geographies around the world, including the Asia-Pacific region, in the fight against cancer.
以中文版本为起点,开发官方网站的多语种版本，是Cure4Cancer战略的第一步。作为一个全球性的合作项目，C4C致力于联合包括亚太地区在内，全球使用各种语言、来自各个地域的利益攸关方，携手抗击人类的共敌：癌症。
The main barrier to finding life-saving new cancer treatments or prevention is the time it takes to conduct clinical trials. Over 19 million new cancer cases are diagnosed worldwide every year, but due to a lack of patient awareness, only less than 5% enroll in clinical trials despite the fact that they are widely recognized as providing the most advanced cancer treatments.
进行临床试验所需的高昂时间成本，是探索拯救生命的癌症治疗或预防新方法的主要障碍。全世界每年新诊断出的癌症病例超过1900万个，但由于缺乏患者意识，尽管临床试验被广泛认为是提供最先进癌症治疗方法的途径，但实际只有不到5%的患者参加了临床试验。
Bureaucratic red tape and a lack of coordination between government regulatory agencies in different countries also limit clinical trials. Better international standardization of clinical trials and their approvals has proven capable of shortening the time needed to roll out a new cancer treatment from 15 years to two or three years. Better standardization could help 10% of all cancer patients reduce their risk of death by 10% to 20% annually, representing one to two million lives saved every year.
官僚主义的冗杂及不同国家政府监管机构之间协同不足，也限制了癌症研发临床试验的发展。事实证明，更高质量的临床试验及其全球监管的标准化，有望将一种新的癌症治疗方法的审批时间从15年缩短到两至三年。国际标准化的完善更可以帮助全球10%的癌症患者每年减少10%到20%的死亡风险：这意味着每年可以挽救一百到两百万的宝贵生命。
The new C4C website, first launched in English in early March, brings together key information about patients’ personal journeys with clinical trials, how to find and join a study, and the history of international clinical trials collaboration.
新版C4C网站于2023年3月初首次推出英文版本。该网站汇集了关于患者个人的临床试验历程分享、寻找和申请加入研究以及国际临床试验的指导方法、国际临床试验合作的历史时间线等重要信息。
Dr. Bob Li, Medical Oncologist and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center; Senior Fellow on Global Public Health at the Asia Society Policy Institute’s Center for China Analysis, said: “Clinical trials are the critical step of translating scientific discovery into saving lives. It currently takes on average 10 to 15 years to develop any new therapeutics because we work in silos and simply can’t find the right patients in need for the right treatment. We have now done proof of concept to show that we can lead these breakthroughs in a much quicker time frame of 2-3 years if we break down the silos in a multiregional, international fashion.”
纪念斯隆-凯特琳癌症中心（MSK斯隆）肿瘤内科医生、中国及亚太地区医生大使、亚洲协会政策研究所中国分析中心全球公共卫生高级研究员李廷侃教授说： “临床试验是将科学发现转化为拯救生命的关键步骤。目前，开发一种新的治疗方法平均需要花费10至15年，这是因为我们在孤军奋战，很难为合适的疗法匹配到合适的患者。我们现在已经完成概念验证，结果表明，如果我们以多区域、国际化的方式打破“孤岛”式的旧模式，我们有望，将引领科学突破的时间线刷新缩短至2-3年。”
Jing Qian, Co-Founder and Managing Director of the Asia Society Policy Institute’s Center for China Analysis, said: “Cancer is a common, transnational enemy of humanity, but it can be fixed. Better international coordination and harmonization of cancer clinical trials could save as many as two million lives every single year. Our international Cure4Cancer movement seeks to raise public awareness of the extremely undervalued potential of international clinical trials as well as to empower more policy innovations and promote patient-centric treatments globally.”
"癌症是不分国界的人类共敌。但只要齐心，我们可以聚爱愈癌",亚洲协会中国分析中心联合创始人兼常务董事钱镜说："最近我们在哈佛发布的研究报告充分表明：在癌症临床试验上更充分全面的国际合作，可以让我们有机会每年多拯救一、两百万条性命。Cure4Cancer（聚爱愈癌，C4C）国际合作项目正是为此而生 —— 旨在提高全球公众对国际临床试验在治愈癌症方面被极度低估的潜力的认识，以及在全球范围内赋能更多的政策创新，以进一步促进以患者为中心的治疗，带给患者，及其家人，乃至全人类更大的和平与福祉。"
To speak with Jing Qian or any of our other experts at Asia Society Policy, please reach out to pr@asiasociety.org. To speak with Dr. Bob Li at Memorial Sloan Kettering Cancer Center, please reach out to williamr@mskcc.org.
如需与钱镜或亚洲协会的其他专家联系交流，请联系 pr@asiasociety.org。如需与纪念斯隆-凯特琳癌症中心（MSK斯隆）的Bob Li教授联系交流，请联系williamr@mskcc.org。